Infusion regimen of piperacillin-tazobactam for pneumonia in older adults
Model-Guided Dose Optimization vs. Empirical Dosing of Piperacillin-Tazobactam in the Treatment of Pneumonia in Elderly Patients: A Study on Superiority
This study tests which way of giving an antibiotic for pneumonia works better for older adults, either every 6 hours or every 8 hours, to help them recover more effectively.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 42 (estimated) |
| Ages | 65 Years to 100 Years |
| Sex | All |
| Sponsor | Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06972537 on ClinicalTrials.gov |
What this trial studies
This study investigates the optimal infusion regimen of piperacillin-tazobactam, a broad-spectrum antibiotic, in patients aged 65 and older diagnosed with pneumonia. It compares two different infusion schedules: every 6 hours for 4 hours versus every 8 hours for 3 hours, aiming to determine which regimen achieves better drug concentration compliance. The research is motivated by the high incidence and mortality rates of pneumonia in the elderly and seeks to provide evidence that could enhance treatment protocols for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 65 and older who have a clinical diagnosis of pneumonia and are receiving intravenous piperacillin-tazobactam treatment.
Not a fit: Patients with a history of allergy to β-lactam antibiotics, those undergoing continuous renal replacement therapy, or individuals with severe organ dysfunction or malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment outcomes for elderly patients with pneumonia by optimizing antibiotic administration.
How similar studies have performed: While there is limited research specifically targeting infusion regimens in the elderly population, similar studies on antibiotic dosing strategies have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age must be greater than 65 years Clinical diagnosis of Pneumonia Receiving intravenous piperacillin-tazobactam treatment Exclusion Criteria: History of allergy to β-lactam antibiotics Continuous renal replacement therapy, severe organ dysfunction Malignant tumor disease
Where this trial is running
Jinan, Shandong
- Second hospital of Shandong university — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Wei Zhao, Ph.D
- Email: zhao4wei2@hotmail.com
- Phone: 86053188383308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.